NAMPT and cancer: Significantly decreased levels of butyrylcarnitine in a dose-dependent fashion (Fig. 3) suggest a NAMPT inhibition effect on de novo fatty acid synthesis, which was earlier reported to be reduced in different cancer cells when treated with FK866 [48].